Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華控康泰集團有限公司
Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO A DISCLOSEABLE AND CONNECTED TRANSACTION

Reference is made to the announcement of Kontafarma China Holdings Limited (the "**Company**") dated 18 August 2025 in relation to the Beijing Construction Contract for the Beijing R&D Complex Project (the "**Announcement**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, a circular (the "**Circular**") containing, among other things, (i) further information on the Beijing Construction Contract and the transaction contemplated thereunder; (ii) the recommendations of the Independent Board Committee to the Independent Shareholders; (iii) a letter from the Independent Financial Advisor containing its advice in connection with the aforesaid; and (iv) the notice convening the EGM together with the proxy form, was expected to be despatched to the Shareholders on or before 8 September 2025.

As additional time is required to finalise certain information to be included in the Circular, the Company is applying to the Stock Exchange for a waiver from strict compliance with the requirements of Rule 14.41(a) of the Listing Rules and it is currently expected that the despatch date of the Circular will be postponed to a date on or before 30 September 2025.

By order of the Board of
Kontafarma China Holdings Limited
Wang Feifei
Chairman

Hong Kong, 5 September 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Feifei (Chairman and President), Ms. Qiao Linna, Ms. Guo Zixiu (Financial Controller) and Mr. Liu Jiankun; one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming, and Mr. Yao Xiaomin.